SEATTLE–(BUSINESS WIRE)–Sound Pharmaceuticals is pleased to announce that it completed enrollment of its second Phase 3 open label study of SPI-1005 for the Treatment of Meniere’s Disease (MD).
Read More
SEATTLE–(BUSINESS WIRE)–Sound Pharmaceuticals (SPI) is pleased to announce that the FDA has granted its investigational new drug, SPI-1005, Breakthrough Therapy Designation (BTD) for the treatment of hearing loss in patients with Meniere’s disease (MD).
Read More
SEATTLE — Sound Pharmaceuticals is pleased to announce that it has been invited to present its R&D and financing goals at two upcoming industry conferences this month.
Read More
SEATTLE — Sound Pharmaceuticals is pleased to announce that it will make four presentations (listed below) at the upcoming Association for Research in Otolaryngology MidWinter Meeting in Orlando, FL.
Read More
Sound Pharma Announces Positive Phase 3 Results for the Treatment of Meniere’s Disease with SPI-1005
SEATTLE — Sound Pharmaceuticals is pleased to announce that the pivotal Phase 3 clinical trial involving SPI-1005, a novel anti-inflammatory compound (ebselen), for the treatment of Meniere’s Disease (STOPMD-3), achieved its co-primary endpoints for efficacy involving improvements in hearing loss and speech discrimination.
Read More
SEATTLE — Sound Pharmaceuticals is pleased to announce that the Phase 3 clinical trial involving SPI-1005, a novel anti-inflammatory, for the treatment of Meniere’s Disease (STOPMD-3) has been completed.
Read More
SEATTLE & INNSBRUCK, Austria– Sound Pharmaceuticals (SPI) is pleased to announce that it has received FDA notification that its Investigational New Drug Application (IND) may proceed involving SPI-1005 treatment and cochlear implantation (CI).
Read More
Sound Pharmaceuticals (SPI) will present the Phase 2b STOP Ototoxicity data that was selected for podium presentation at the Association for Research in Otolaryngology (ARO) Midwinter Meeting in Anaheim, CA (February 3-7).
Read More
Sound Pharmaceuticals is pleased to announce that it has completed enrollment in its first Phase 3 clinical trial involving SPI-1005, a novel anti-inflammatory, for the treatment of Meniere’s Disease (STOPMD-3).
Read More
Sound Pharmaceuticals is pleased to announce that it has enrolled the first patient in its Phase 3 clinical trial involving SPI-1005 for the Treatment of Meniere’s Disease (STOPMD-3). Additionally, this marks the first Phase 3 trial of an investigational new drug for the treatment of Meniere’s Disease (MD).
Read More
